drug

FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

October 31, 2025 16:30 ET  | Source: FibroBiologics, Inc. Advancing preparations to begin manufacturing of fibroblast-based spheroids product candidate, CYWC628,…

4 days ago

Bright Minds Biosciences toPresent at Upcoming Conferences

October 30, 2025 18:30 ET  | Source: Bright Minds Biosciences NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bright Minds…

5 days ago

Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes

LEHI, Utah, Oct. 23, 2025 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering therapies that target the root causes…

2 weeks ago

Global Drug Delivery Systems (DDS) Market Transforms Amid New Pharma Demands

FRAMINGHAM, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Alira Health today released its 2025 Global Drug Delivery System Trends Report,…

2 weeks ago

Cambrex Unveils $120 Million Investment to Expand API Manufacturing and Strengthen U.S. Drug Supply Resilience

EAST RUTHERFORD, N.J., Oct. 22, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced a…

2 weeks ago

Curia Sterile Drug Product Facility Named Massachusetts Manufacturer of the Year

ALBANY, N.Y., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), a leading contract research, development and manufacturing organization,…

2 weeks ago

Jubilant Biosys Limited Seals Deal with Pierre Fabre SA

To acquire R&D center at Saint-Julien-en-Genevois, France To add Drug Discovery & Preclinical Development capabilities in Biologics & Antibody Drug…

2 weeks ago

Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platforms Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung Cancer

Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and remains an aggressive disease with median survival…

2 weeks ago

Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner’s National Priority Voucher Pilot Program

REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing…

3 weeks ago